Fibromyalgia: Symptoms, Diagnosis, Treatment & Monitoring

Fibromyalgia (also called fibromyalgia syndrome or FMS) is a chronic disorder of central pain regulation in which the brain and spinal cord amplify pain signals so that ordinary stimuli are perceived as painful and minor pain becomes severe. Functional imaging studies have repeatedly shown altered processing in pain-sensing networks; the historic “tender point” model has been superseded by this central sensitisation framework. Routine joint imaging, inflammatory markers and structural muscle biopsies are typically unremarkable, which is why the diagnosis is clinical and the investigations are exclusionary rather than confirmatory.

The condition is most commonly diagnosed in middle-aged adults and disproportionately affects women, but it occurs in men, adolescents and older adults too. Comorbidity is the rule rather than the exception: patients frequently carry overlapping diagnoses such as chronic fatigue syndrome, irritable bowel syndrome, migraine, interstitial cystitis and chronic pelvic pain. Because the pain is real but the workup is bland, patients often describe years of being dismissed before a diagnosis is settled — that history influences how willing they are to engage with the rehabilitative programme that actually drives outcome.

The 2016 revision of the American College of Rheumatology criteria combines the older 2010/2011 sets, fixes the regional-pain misclassification that affected the earlier versions, and is now used as both a diagnostic and a research tool. Two scores are computed at the bedside.

↔On a small screen, swipe or scroll sideways to see the full table.

A polysymptomatic distress (PSD) score of 12 or more is widely used in research as a continuous severity index combining WPI and SSS — useful at the bedside for tracking trajectory between reviews even when a formal criteria reassessment is not needed.

The clinical picture is multidimensional. Pain is usually the headline complaint, but the impact on function comes from the overlap of pain, sleep, fatigue, mood and cognition. Patients often describe waxing-and-waning days punctuated by post-exertional flares; severity over the 24 hours after a busy shift or a long appointment day is more revealing than a single visit-day pain score.

Typical features

• Chronic widespread muscle pain and aching across upper and lower body and the axial spine, often described as deep, burning or throbbing.
• Persistent fatigue that is disproportionate to activity and only partially relieved by rest, frequently with daytime excessive sleepiness.
• Unrefreshing sleep and frequent insomnia, with patients reporting they wake feeling “run over” regardless of total sleep time.
• Cognitive slowing — slowed retrieval, attention lapses, working-memory failures clustered as “fibro fog” — overlapping with our notes on memory problems.
• Tenderness to ordinary touch (allodynia) and amplified pain to pressure (hyperalgesia) — a clinical correlate of central sensitisation.
• Recurrent headache (tension-type or migrainous) and overlapping back pain.
• Coexisting mood symptoms — low mood mapped via our hub on depression as a symptom and prominent anxiety — that are frequent but not universal.

Easily missed or atypical features

• Distal numbness and tingling with normal nerve conduction — central in origin in fibromyalgia, but small-fibre neuropathy still warrants exclusion when the pattern is genuinely length-dependent.
• Functional gastrointestinal symptoms (bloating, alternating bowel habit, recurrent abdominal pain) overlapping with irritable bowel syndrome.
• Dysautonomic features — orthostatic dizziness, palpitations on standing, temperature dysregulation — that overlap with postural orthostatic tachycardia syndrome.
• Atypical pelvic and bladder symptoms when coexistent endometriosis or interstitial cystitis is missed.
• Sensitivity to light, sound, smell and temperature that disproportionately limits work and home routines but rarely makes it onto the problem list.

Mechanism in plain language

This central-nervous-system framing matters at the bedside. It explains why cyclobenzaprine and tricyclics work better than NSAIDs, why an SNRI such as duloxetine modulates descending pathways, and why structured exercise — which appears counter-intuitive for an exhausted patient — improves outcomes by retraining sensorimotor and autonomic networks rather than by building peripheral muscle bulk.

Risk profile that should change the clinical lens

• Female sex (current diagnostic criteria detect women more readily; men are likely under-diagnosed).
• Family history of fibromyalgia or chronic pain conditions, suggesting a polygenic susceptibility.
• Coexisting rheumatic disease — rheumatoid arthritis, lupus, ankylosing spondylitis, osteoarthritis — that adds a peripheral nociceptive driver to the central syndrome.
• History of physical trauma (whiplash, surgery, prolonged hospitalisation) or psychological trauma (PTSD, adverse childhood experiences) that primed central sensitisation.
• Sleep-disordered breathing, restless legs and other primary sleep disorders that drive the unrefreshing-sleep loop.
• Mood disorders (depression, anxiety) that share neurobiology with central pain pathways and shape coping capacity.
• Post-infectious states — viral illnesses, including post-COVID syndromes — that can act as inflection points.

Diagnosis is a clinical process. The aim is two-fold: confirm that the pattern fits the 2016 ACR criteria and exclude the mimics that demand a different management pathway. Tender point examination is no longer required by current criteria.

Clinical assessment

• Pain map: have the patient mark the painful regions over the previous week — quick, reproducible, and immediately scorable into the WPI.
• Sleep history: quality, timing, snoring/witnessed apnoeas, restless legs symptoms, daytime alertness.
• Cognitive complaints: word-finding, attention lapses, executive slowing — separate from objective decline that would warrant cognitive screening.
• Mood screen: structured tools (e.g. PHQ-9, GAD-7) to flag treatable comorbidity rather than to confirm fibromyalgia.
• Functional status: hours of meaningful activity per day, work or carer impact, reliance on others — better outcome anchors than a pain score alone.
• Targeted physical examination: joint counts, synovitis check, neurological screen, proximal strength testing, lymph node and skin survey to flag mimics.
• Structured pain assessment capturing intensity, distribution, character and impact in one place.

Laboratory investigations — exclusion-focused, not confirmatory

• Inflammatory and blood basics: complete blood count, ESR, CRP and CMP to flag inflammation, anaemia or organ dysfunction.
• Endocrine: thyroid-stimulating hormone to exclude hypothyroidism; consider vitamin B12 when paraesthesia or cognitive complaints lead.
• Iron status: ferritin when fatigue and restless legs dominate.
• Autoimmune screen — directed only: ANA and rheumatoid factor when synovitis, sicca features or characteristic rashes are present; avoid blanket panels in their absence because false positives muddle the picture.
• Other targeted tests based on history: vitamin D in deficient populations, hepatitis serology in iv-drug users, tryptase if mast-cell features dominate, creatine kinase when objective weakness is found.

Imaging and physiological diagnostics

• Reserve plain radiographs and MRI for joints with persistent localising signs (effusion, deformity, focal weakness) — generic “whole body MRI” for diffuse pain rarely changes management.
• Refer for sleep study (polysomnography) when snoring, apnoeas, refractory daytime sleepiness or BMI elevation suggest obstructive sleep apnoea.
• Cardiology investigations for orthostatic palpitations or syncope; document lying and standing observations using your local vital signs measurement protocol.
• Targeted neurological assessment when paraesthesia, weakness or dyssynergia raises a focal differential.

A staged approach prevents both over-investigation (pan-imaging, broad autoimmune fishing) and under-treatment (settling on “probably fibro” without ruling out treatable mimics).

1. Detection: any patient with widespread pain and disabling fatigue/sleep disturbance ≥3 months should trigger a structured fibromyalgia assessment rather than serial reactive analgesia prescriptions.
2. Threshold: apply the ACR 2016 criteria in the first review; do not rely on tender-point counts.
3. Mimic exclusion: pursue the targeted laboratory and imaging investigations above based on the directed examination findings — a normal panel does not confirm fibromyalgia, but an abnormal one redirects management.
4. Education and pacing first: introduce the central-sensitisation framing, set realistic outcome expectations, and start a graded exercise plan before reaching for medication.
5. Pharmacology when needed: step in with duloxetine (or pregabalin, or low-dose amitriptyline depending on symptom profile and comorbidity) when severe pain or sleep disruption persists despite non-pharmacological care — review at 4–8 weeks.
6. Multimodal escalation: involve physiotherapy, psychology and pain medicine when single-agent therapy fails or polypharmacy and complex psychiatric overlap dominate.
7. Reassess for new disease: if the pattern changes (new synovitis, weight loss, fevers, focal deficit), reopen the differential rather than escalating central-pain medication.

Mimics range from missed inflammatory disease to under-recognised endocrine or neurological pathology. The 2016 criteria explicitly allow coexistence — these conditions are mimics in the sense that they require their own treatment pathway, not that they exclude fibromyalgia.

↔On a small screen, swipe or scroll sideways to see the full table.

The EULAR 2016 framework sets a graduated, shared decision-making approach. Education and non-pharmacological care anchor management; medication is added when symptoms remain severe or function plateaus despite that foundation.

First-line: education and non-pharmacological care

• Patient education reframing fibromyalgia as a real central pain syndrome with effective management — corrects the “it is all in your head” narrative many patients arrive with.
• Graded aerobic exercise (walking, cycling, swimming) is the only ‘strong for’ EULAR therapy-based recommendation; start at very low intensity and titrate by perceived exertion to avoid post-exertional flares.
• Resistance and stretching work as tolerated, ideally physiotherapy-supervised in early weeks.
• Aquatic exercise, tai chi and yoga have evidence in chronic widespread pain and are well tolerated by deconditioned patients.
• Cognitive behavioural therapy (face-to-face or internet-delivered) for mood, coping and pain catastrophising components.
• Sleep hygiene, pacing strategies and ergonomic review of work and home tasks to flatten flare cycles.

Pharmacological options — symptom-targeted

• Duloxetine (an SNRI) — first-line in many guidelines for severe pain with mood overlap; titrate to target dose with anti-emetic counselling and BP review.
• Pregabalin — first-line option for severe pain and disturbed sleep; counsel about sedation, dizziness and weight gain; gabapentin is an off-label alternative used in similar contexts.
• Low-dose amitriptyline at night — pain plus sleep benefit; counsel about anticholinergic effects, falls and morning sedation; nortriptyline may be better tolerated in older adults.
• Cyclobenzaprine (low dose at night) — short-term use for sleep and muscle pain in selected patients.
• Milnacipran where available — another SNRI with an evidence base specific to fibromyalgia.
• Antidepressants for mood comorbidity — e.g. sertraline or fluoxetine — chosen for the depression rather than as analgesia; venlafaxine is sometimes used when SNRI tolerability is preferred.
• Tramadol — only opioid with weak EULAR support and only for severe pain; avoid combining with serotonergic agents and watch for serotonin syndrome; restrict tramadol to short, supervised courses.
• Low-dose naltrexone — emerging evidence for pain reduction; specialist-initiated in jurisdictions where it is used.
• Sleep adjuncts such as melatonin may help when circadian rhythm disturbance dominates, as a step before sedative–hypnotics.

Generally not recommended

• NSAIDs as monotherapy and routine acetaminophen — limited evidence in central pain, and NSAIDs add gastrointestinal, renal and cardiovascular risk for a marginal analgesic gain.
• Long-term opioids — worsen function, encourage opioid-induced hyperalgesia, and add dependency and falls risk; a guideline-divergent decision belongs to specialist pain medicine, not routine primary care.
• Systemic corticosteroids — no role outside treating a coexisting inflammatory disease.
• Cannabinoids — evidence remains insufficient for routine recommendation; weigh local regulation, individual context and specialist input.

Special populations

• Older adults: minimise anticholinergic burden, prefer nortriptyline over amitriptyline, integrate fall risk assessment; co-check polypharmacy via formal medication reconciliation at every transition.
• Pregnancy and lactation: shift to non-pharmacological care; review tricyclics, SNRIs and pregabalin with obstetric and pharmacy input.
• Adolescents: avoid pregabalin and SNRIs as first-line; emphasise pacing, school accommodations and family-centred CBT.
• Coexisting bursitis or osteoarthritis flares: treat the peripheral driver promptly; do not assume every flare is central.

Workflow drives outcomes: clear documentation, planned reviews and explicit treatment-failure criteria stop the drift toward open-ended polypharmacy that is the most common iatrogenic harm in fibromyalgia care.

• Documentation: record the WPI/SSS or PSD score at baseline and again at each review; track function (hours of meaningful activity, work status, dependency on help) alongside pain.
• Monitoring cadence: review every 2–4 weeks during titration of a new agent; once stable, every 3–6 months in primary care; sooner if function declines.
• Treatment failure criteria: escalate or switch agents if no meaningful pain or functional change after 4–8 weeks at target dose, if adverse effects outweigh benefit, or if the patient cannot reliably tolerate or adhere to the regimen.
• Referral thresholds: rheumatology when an inflammatory mimic is plausible; pain medicine for refractory pain or complex polypharmacy; psychiatry/psychology for depressive, anxiety or PTSD overlap; sleep medicine where polysomnography is needed.
• Multidisciplinary roles: physiotherapy (graded exercise), occupational therapy (pacing tools and work adjustments), pharmacy (interactions and tapering), psychology (CBT and pain self-management), social work (benefits, school or workplace adjustments).
• Safeguarding awareness: in severe cases, social isolation, financial precarity and suicidal ideation are real risks — screen explicitly rather than assuming primary care visit space is sufficient.

Bedside monitoring checklist

• Pain map plus brief function statement — “What did you actually manage to do today?” — at every contact.
• Sleep quality and duration the preceding 3 nights, plus any new daytime sleep events.
• Mood screen at intervals defined by local protocol; revisit when therapy is escalated or function deteriorates.
• Medication review for sedation, anticholinergic burden, serotonergic load and falls — particularly in older adults.
• Lying-and-standing observations when orthostatic symptoms emerge.

Short-term

• Disabling pain flares triggered by sleep loss, infection, weather change or psychological stress.
• Adverse effects of pharmacotherapy — sedation and falls (tricyclics, pregabalin), nausea and BP rise (duloxetine, venlafaxine), serotonergic interactions (tramadol).
• Iatrogenic harm from over-investigation (false-positive autoimmune panels) or escalating opioid prescribing in primary care.

Medium and long-term

• Functional decline, deconditioning and loss of work or caregiving capacity.
• Mood disorders (depression, anxiety) and, in severe cases, suicidal ideation — disability and chronic pain together raise risk.
• Polypharmacy and dependence when sedative or opioid prescribing drifts upward without structured review.
• Diagnostic overshadowing: new disease (malignancy, inflammatory disease, neurological pathology) attributed to fibromyalgia and missed.
• Family and relationship strain reflecting invisible disability.

Primary prevention is not established. Clinician-facing prevention is really early identification and secondary prevention of decline: identify widespread chronic pain promptly, treat sleep-disordered breathing and mood comorbidity early, support pacing after viral or post-surgical insults, and avoid the iatrogenic cascade of opioid escalation. In coexisting rheumatic disease, treat the inflammatory driver to target while also addressing the central pain component — this prevents unnecessary biologic intensification on the assumption that all residual pain is inflammatory.

Fibromyalgia is a long-term condition, but it is not progressive in the way an inflammatory or degenerative disease is — life expectancy is broadly normal. Trajectory varies: a minority improve substantially, most experience a fluctuating course with periods of better and worse function, and a smaller subset remain severely disabled. The strongest predictors of better function are adherence to graded exercise, treatment of comorbid depression, anxiety and sleep apnoea, employment retention through workplace accommodations, and continuity with a small clinician team rather than fragmented care. Outcome conversations should be honest about persistence while keeping the focus on functional gains rather than pain elimination.

Listening and language

Patients arrive with histories of dismissal. Begin by validating the reality of the pain and the diagnosis — “This is a real central nervous system condition with an evidence-based plan” — and frame the workup as ruling out other things that need different treatment, not as proving the patient is ill. The therapeutic alliance built in the first conversation predicts adherence to the rehabilitative work that drives outcome.

Subtle deterioration

Watch for new red flags rather than escalating central-pain pharmacology when “the pain is just worse”. New synovitis, weight loss, fever, focal deficit, abrupt mood collapse with suicidal ideation, severe orthostatic decompensation — each deserves directed investigation, not another titration.

Communication challenges

Cognitive symptoms make appointment recall and complex regimens harder. Provide written or printed summaries, agree one or two changes per visit, and use teach-back for new medications. Coordinate translation services for migrant populations whose pain narratives may not map onto familiar idioms.

Documentation and safety netting

On every contact: confirmed criteria status (or pending mimic exclusion), current medications and doses, latest function statement, mood screen result, next planned review and the threshold for earlier contact. Make explicit who the patient should call if function collapses or mood deteriorates between appointments — vague “return as needed” advice is too thin a safety net for this group.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of fibromyalgia recognition (ACR widespread-pain / symptom-severity criteria), structured non-pharmacological + duloxetine / pregabalin / amitriptyline ladder, mental-health / sleep / function support and the missed-inflammatory-disease / cauda-equina / suicidality red flags.